Senior Oncology Medical Science Liaison

Sumitomo Pharma America, Inc; Field (KY); Hybrid; USD 163,000 - 204,000; Full time

Benefits offered by this job

Merit raises

Incentive plan

401(k) plan

Medical insurance

Dental insurance

Vision insurance

Paid time off

Holidays

Sick leave

Job summary

Sumitomo Pharma America, Inc. is seeking a dynamic Medical Science Liaison (MSL) to integrate scientific expertise with medical strategies and to build cohesive relationships with key opinion leaders and regional clinicians. The MSL will support exchange of scientific information and collaboration across the company’s development portfolio.

The position covers Illinois, Indiana, Kentucky and Michigan. Travel is extensive (60–80% of time) and final title/ compensation will be determined by

Responsibilities

• Identify and engage national, regional, and local Oncology thought leaders and HCPs.
• Serve as the primary scientific contact and build long-term peer to peer scientific relationships.
• Exchange scientific and technical information relevant to the company’s development portfolio.
• Support relationships between key opinion leaders and internal product teams.
• Educate priority HCPs on research and development initiatives.
• Gather medical insights to inform clinical and marketing strategies.
• Provide an overview of company areas of interest for investigator sponsored studies
• Contribute to internal educational activities and training.
• Represent the company at Oncology conferences and scientific meetings.
• Lead relevant projects within the field medical organization.

Job description

Sumitomo Pharma America, Inc. is seeking a dynamic Medical Science Liaison (MSL) to integrate scientific expertise with medical strategies and to build cohesive relationships with key opinion leaders and regional clinicians. The MSL will support exchange of scientific information and collaboration across the company’s development portfolio.

The position covers Illinois, Indiana, Kentucky and Michigan. Travel is extensive (60–80% of time) and final title/ compensation will be determined by